HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuki Ohkawa Selected Research

Focal Adhesion Protein-Tyrosine Kinases

8/2016A therapeutic trial of human melanomas with combined small interfering RNAs targeting adaptor molecules p130Cas and paxillin activated under expression of ganglioside GD3.
12/2012Disialyl gangliosides enhance tumor phenotypes with differential modalities.
3/2008Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuki Ohkawa Research Topics

Disease

19Neoplasms (Cancer)
11/2022 - 08/2010
14Melanoma (Melanoma, Malignant)
10/2022 - 03/2008
11Inflammation (Inflammations)
01/2021 - 12/2009
6Glioma (Gliomas)
09/2021 - 06/2015
5Alzheimer Disease (Alzheimer's Disease)
08/2021 - 12/2009
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2021 - 09/2011
3Neoplasm Metastasis (Metastasis)
01/2021 - 10/2010
3Nervous System Diseases (Neurological Disorders)
08/2020 - 01/2019
2Glioblastoma (Glioblastoma Multiforme)
01/2021 - 01/2021
2Hereditary Spastic Paraplegia
08/2020 - 01/2019
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2018 - 12/2012
1Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)
11/2022
1Brain Neoplasms (Brain Tumor)
01/2021
1Thrombosis (Thrombus)
01/2021
1Emphysema
01/2021
1Chronic Obstructive Pulmonary Disease (COPD)
01/2021
1Neuroblastoma
04/2018
1Dementia (Dementias)
09/2016
1Rheumatoid Arthritis
04/2016
1Experimental Arthritis
04/2016
1Arthritis (Polyarthritis)
04/2016
1Lymphoma (Lymphomas)
01/2016
1Neuroinflammatory Diseases
04/2015
1Osteosarcoma (Osteogenic Sarcoma)
12/2012
1Carcinogenesis
08/2011

Drug/Important Bio-Agent (IBA)

16GangliosidesIBA
12/2021 - 03/2011
11GD3 ganglioside (GD(3))IBA
08/2021 - 03/2008
9GlycolipidsIBA
01/2022 - 12/2009
9EnzymesIBA
12/2021 - 01/2016
6Complement System Proteins (Complement)IBA
03/2020 - 12/2009
6GlycosphingolipidsIBA
05/2019 - 12/2012
5PaxillinIBA
10/2022 - 03/2008
5Proteins (Proteins, Gene)FDA Link
10/2022 - 05/2011
4Polysaccharides (Glycans)IBA
11/2022 - 01/2021
4GlycosyltransferasesIBA
01/2021 - 01/2016
4LipidsIBA
03/2020 - 03/2011
4N-Acetylneuraminic Acid (Sialic Acid)IBA
04/2018 - 12/2012
3AntigensIBA
01/2022 - 01/2016
3IntegrinsIBA
12/2021 - 08/2008
3Biological ProductsIBA
01/2021 - 10/2010
3Focal Adhesion Protein-Tyrosine KinasesIBA
08/2016 - 03/2008
2Keratan SulfateIBA
10/2022 - 01/2021
2CarbohydratesIBA
01/2022 - 09/2016
2GD2 gangliosideIBA
12/2021 - 01/2018
2src-Family KinasesIBA
09/2021 - 05/2011
2Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
09/2021 - 06/2015
2CytokinesIBA
08/2021 - 12/2009
2Phosphotransferases (Kinase)IBA
01/2021 - 06/2015
2Pharmaceutical PreparationsIBA
01/2021 - 12/2019
2SugarsIBA
01/2021 - 04/2016
2Small Interfering RNA (siRNA)IBA
08/2016 - 03/2008
2AntibodiesIBA
04/2016 - 01/2016
2Tyrosine (L-Tyrosine)FDA Link
08/2008 - 03/2008
1Neoplasm Antigens (Tumor Antigens)IBA
01/2022
1Matrix Metalloproteinases (MMPs)IBA
09/2021
1A-Form DNA (A-DNA)IBA
09/2021
1DNA (Deoxyribonucleic Acid)IBA
08/2021
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
08/2021
1ChemokinesIBA
08/2021
1Glycoproteins (Glycoprotein)IBA
01/2021
1tyrosine receptor (receptor, tyrosine)IBA
01/2021
1LigandsIBA
01/2021
1MonosaccharidesIBA
01/2021
1NucleotidesIBA
01/2021
1FucosyltransferasesIBA
01/2021
1ProdrugsIBA
01/2021
1FucoseIBA
01/2021
1Proteoglycans (Proteoglycan)IBA
01/2021
1xylosidesIBA
01/2021
1TransferasesIBA
01/2021
1Carboxylesterase (Hydrolase S)IBA
01/2021
1N-AcetylglucosaminyltransferasesIBA
01/2021
1Glycoside Hydrolases (Endoglycosidases)IBA
01/2021
1DisaccharidesIBA
01/2021
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2021
1Deoxyglucose (2 Deoxy D glucose)IBA
10/2020
1AsparagineIBA
10/2020
1Indicators and Reagents (Reagents)IBA
08/2020
1Nonsense Codon (Nonsense Mutation)IBA
08/2020
1AminoglycosidesIBA
08/2020
1dolichyl-diphosphooligosaccharide - protein glycotransferase (oligosaccharyltransferase)IBA
12/2019
1Tumor Biomarkers (Tumor Markers)IBA
05/2019
1Complementary DNA (cDNA)IBA
04/2018
1Amino Acid Transport Systems (Amino Acid Transporter)IBA
01/2018
1Peptides (Polypeptides)IBA
09/2016
1Amyloid (Amyloid Fibrils)IBA
09/2016
1atelocollagenIBA
08/2016
1acetyl 4-aminosalicylic acidIBA
04/2016
1Anti-Citrullinated Protein AntibodiesIBA
04/2016
1Immunoglobulin G (IgG)IBA
04/2016
1ST6GalNAc V brain-specific GD1alpha synthaseIBA
01/2016
1ganglioside M1b (GM1b)IBA
01/2016
1Monoclonal AntibodiesIBA
01/2016
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
01/2016
1neogeninIBA
01/2016
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
06/2015
1CDw17 antigen (lactosylceramide)IBA
04/2015
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2014

Therapy/Procedure

2Immunotherapy
01/2022 - 05/2019
2Therapeutics
01/2021 - 05/2019